CERENOME, INC. — SEC Form D Filing

CERENOME, INC. filed an SEC Form D on September 18, 2026, reporting $3.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 18, 2026
Amount reported
$3.00M
Round stage
Series B+
Industry
Biotechnology
Website
https://cerenome.com/

What the company does

Securities: Equity, Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Central Nervous System (CNS) cancers present complex, interconnected clinical challenges that have seen limited progress with isolated innovations. There is a need for a more connected approach to improve how these diseases are detected, treated, and understood, as conventional therapies often cannot deliver effective outcomes.

Solution

Cerenome is building an integrated CNS oncology platform that connects precision diagnostics (CNSide®), targeted radiotherapeutics (REYOBIQ™), and clinical data insights. This system aims to improve outcomes for patients with CNS cancers by strengthening each capability through a unified approach.

Why now

Advances in precision diagnostics, targeted therapies, and AI for clinical data analysis now allow for a more integrated approach to CNS oncology, which was previously fragmented.

Verdict

Investors backed a platform play integrating diagnostics and therapeutics for CNS cancers, betting on the ability to operationalize a unified approach where others had failed to connect fragmented point solutions. This cleared because the ambition of a full-stack solution offered a larger addressable market and value capture, not because its individual components represented breakthrough science beyond existing benchmarks. The limited upside stemmed from the significant execution risk inherent in simultaneously developing and commercializing precision diagnostics, novel therapeutics, and data insights under one roof, requiring extensive regulatory and market access coordination.

Source: SEC EDGAR Form D filing